Who should not take Tirzepatide?
Documented caution flags for Tirzepatide include mTC / MEN-2 history and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Tirzepatide is limited.
Documented caution flags for Tirzepatide
- MTC / MEN-2 history
- Pancreatitis history
- Pregnancy / nursing
Reported side effects to weigh
- Nausea
- Constipation
- Reflux
- Fatigue
References
- Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al., NEJM, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — Frías et al., N Engl J Med, 2021
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — Garvey et al., Lancet, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tirzepatide
Full Tirzepatide breakdownTirzepatide what it's used forTirzepatide side effectsTirzepatide how to take itTirzepatide mistakes to avoidTirzepatide half-lifeTirzepatide how long to workTirzepatide legal statusTirzepatide how it workstirzepatide vs semaglutideretatrutide vs tirzepatidetirzepatide vs cagrilintidevk2735 vs tirzepatideAsk the AI Coach
Last updated 2026-06-15.